Cancer combination therapies by angiogenesis inhibitors; a comprehensive review
Open accessThe DOI matches its Crossref record; 226 of the 227 references it cites were found in a registry or an index.
Abstract
Abnormal vasculature is one of the most conspicuous traits of tumor tissue, largely contributing to tumor immune evasion. The deregulation mainly arises from the potentiated pro-angiogenic factors secretion and can also target immune cells' biological events, such as migration and activation. Owing to this fact, angiogenesis blockade therapy was established to fight cancer by eliminating the nutrient and oxygen supply to the malignant cells by impairing the vascular network. Given the dominant role of vascular-endothelium growth factor (VEGF) in the angiogenesis process, the well-known anti-angiogenic agents mainly depend on the targeting of its actions. However, cancer cells mainly show resistance to anti-angiogenic agents by several mechanisms, and also potentiated local invasiveness and also distant metastasis have been observed following their administration. Herein, we will focus on clinical developments of angiogenesis blockade therapy, more particular, in combination with other conventional treatments, such as immunotherapy, chemoradiotherapy, targeted therapy, and also cancer vaccines.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, combinations of multiple anti-angiogenic agents with complementary pro-angiogenic targets, or of anti-angiogenics with other modalities such as immunotherapy, chemotherapy or other modalities, show increased patient benefit and are now widely used treatment options in many cancer types [35].”
From The HIF Axes in Cancer - Angiogenesis, Metabolism and Immune-Modulation (2025) · cites this paper as [35]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
He, Z., Subramaniam, D., Ramalingam, S., Dhar, A., Postier, R. G., Umar, S., Zhang, Y., & Anant, S. (2011) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00159.2011 · Cited by 31
RetractedRor2 signaling regulates Golgi structure and transport through IFT20 for tumor invasiveness
Nishita, M., Park, S.-Y., Nishio, T., Kamizaki, K., Wang, Z., Tamada, K., Takumi, T., Hashimoto, R., Otani, H., Pazour, G. J., et al. (2017) · Scientific Reports · doi:10.1038/s41598-016-0028-x · Cited by 15,947
Tumor angiogenesis: therapeutic implications
Sherwood, L. M., Parris, E. E., & Folkman, J. (1971) · New England Journal of Medicine · doi:10.1056/nejm197111182852108 · Cited by 10,187
A New Era of Systemic Therapy for Hepatocellular Carcinoma with Regorafenib and Lenvatinib
Kudo, M. (2017) · Liver Cancer · doi:10.1159/000462153 · Cited by 5,936
Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer
Sandler, A., Gray, R., Perry, M. C., Brahmer, J., Schiller, J. H., Dowlati, A., Lilenbaum, R., & Johnson, D. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061884 · Cited by 5,761
Bruix, J., Qin, S., Merle, P., Granito, A., Huang, Y.-H., Bodoky, G., Pracht, M., Yokosuka, O., Rosmorduc, O., Breder, V., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(16)32453-9 · Cited by 3,653
Pàez-Ribes, M., Allen, E., Hudock, J., Takeda, T., Okuyama, H., Viñals, F., Inoue, M., Bergers, G., Hanahan, D., & Casanovas, O. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.01.027 · Cited by 2,339
Gray, L. H., Conger, A. D., Ebert, M., Hornsey, S., & Scott, O. C. A. (1953) · The British Journal of Radiology · doi:10.1259/0007-1285-26-312-638 · Cited by 2,158
Immune checkpoint inhibitors: recent progress and potential biomarkers
Darvin, P., Toor, S. M., Sasidharan Nair, V., & Elkord, E. (2018) · Experimental & Molecular Medicine · doi:10.1038/s12276-018-0191-1 · Cited by 2,035
Kerbel, R. S. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0706596 · Cited by 1,948
Research works printed but not linked: 4
- Wu H-C, Huang C-T, Chang D-K. Anti-angiogenic therapeutic drugs for treatment of human cancer. J Cancer Mol. 2008;4(2):37–45.
- Keisner SV, Shah SR. Pazopanib. Drugs. 2011;71(4):443–54.
- Amin A, Plimack ER, Ernstoff MS, Lewis LD, Bauer TM, McDermott DF, et al. Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study. J Immunother Cancer. 2018;6(1):109. · DOI · Paper page
- Salazar R, Capdevila J, Manzano JL, Pericay C, Martínez-Villacampa M, López C, et al. Phase II randomized trial of capecitabine with bevacizumab and external beam radiation therapy as preoperative treatment for patients with resectable locally advanced rectal adenocarcinoma: long term results. BMC Cancer. 2020;20(1):1164. · DOI
Cited by
Angiogenic signaling pathways and anti-angiogenic therapy for cancer
Liu, Z.-L., Chen, H.-H., Zheng, L.-L., Sun, L.-P., & Shi, L. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01460-1 · Cited by 1,300
“Additionally, the combination of angiogenic inhibitors with other conventional cancer treatment including chemotherapy, radiotherapy, immune therapy, adoptive cell therapy, and cancer vaccines has been evidently demonstrated through many pivotal clinical trials among patients with different types of cancer.(47) With t…”
BackgroundVEGF signaling: Role in angiogenesis and beyond
Shaw, P., Dwivedi, S. K. D., Bhattacharya, R., Mukherjee, P., & Rao, G. (2024) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2024.189079 · Cited by 215
Vimalraj, S. (2022) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2022.09.129 · Cited by 186
PEGylated PLGA nanoparticles: unlocking advanced strategies for cancer therapy
Kesharwani, P., Kumar, V., Goh, K. W., Gupta, G., Alsayari, A., Wahab, S., & Sahebkar, A. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02410-x · Cited by 132
“Administering low-dose chemotherapy with medications that target certain biochemical pathways or immunological checkpoints may lead to synergistic effects, hence improving patient outcomes [92].”
Decoding tumor angiogenesis: pathways, mechanisms, and future directions in anti-cancer strategies
Liu, X., Zhang, J., Yi, T., Li, H., Tang, X., Liu, D., Wu, D., & Li, Y. (2025) · Biomarker Research · doi:10.1186/s40364-025-00779-x · Cited by 134
“In addition, numerous pivotal clinical trials have evaluated the combination of angiogenesis inhibitors with traditional cancer therapies such as chemotherapy, radiotherapy, biotherapy, immunotherapy, adoptive cell therapy, and cancer vaccines in patients with various cancer types [22].”
Metadata
- Authors
- Ansari, M. J., Bokov, D., Markov, A., Jalil, A. T., Shalaby, M. N., Suksatan, W., Chupradit, S., AL-Ghamdi, H. S., Shomali, N., Zamani, A., Mohammadi, A., & Dadashpour, M.
- Affiliations
- Prince Sattam Bin Abdulaziz University (SA)
- Sechenov University (RU)
- Industrial University of Tyumen (RU)
- Yanka Kupala State University of Grodno (BY)
- Suez Canal University (EG)
- Chulabhorn Royal Academy (TH)
- Chiang Mai University (TH)
- Al Baha University (SA)
- Tabriz University of Medical Sciences (IR)
- Shiraz University of Medical Sciences (IR)
- Urmia University of Medical Sciences (IR)
- Semnan University of Medical Sciences (IR)
- Corresponding author
- Dadashpour, Mehdi
- ORCID
- Venue
- Cell Communication and Signaling
- Published
- 2022-04-07
- Volume
- 20
- Issue
- 1
- Pages
- 49-49
- ISSN
- 1478-811X (ISSN-L)
- PMC
- PMC8991477
- OpenAlex
- W4223524017
- Cited by
- 197
- References
- 227
- Citations by year
- 2026: 33 · 2025: 47 · 2024: 47 · 2023: 42 · 2022: 28
- FWCI
- 4.27
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Cell Communication and Signaling (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Health Sciences › Medicine › Oncology › Lymphatic System and Diseases
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Keywords
- anti-angiogenic therapy, angiogenesis inhibitors, vascular endothelial growth factor, combination cancer therapy, tumor immune evasion, drug resistance, metastasis, immunotherapy, chemoradiotherapy, targeted therapy, cancer vaccines, tumor vasculature
- MeSH terms
- Humans, Immunotherapy, Neoplasms, Neovascularization, Pathologic, Angiogenesis Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Cancer combination therapies by angiogenesis inhibitors; a comprehensive review. https://app.cochat.ai/papers/10.1186/s12964-022-00838-y
- The paper
- Ansari, M. J., Bokov, D., Markov, A., Jalil, A. T., Shalaby, M. N., Suksatan, W., Chupradit, S., AL-Ghamdi, H. S., Shomali, N., Zamani, A., Mohammadi, A., & Dadashpour, M. (2022). Cancer combination therapies by angiogenesis inhibitors; a comprehensive review. Cell Communication and Signaling. https://doi.org/10.1186/s12964-022-00838-y
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.